ABVX: Bagan rega target Abivax Pharma

ABIVAX (ABVX) is a cutting-edge biopharma company developing treatments for severe inflammation through RNA modification. The operating model relies on full outsourcing of production and testing, which reduces costs. Risks are concentrated in a single flagship intestinal drug, and the indicator stands at 156.62. This historical price chart on the GURU.Markets platform clearly demonstrates the asset value dynamics of this issuer.

This indicator represents the weighted average target price of shares calculated based on the aggregate models of professional analysts. For ABIVAX (ABVX), which has no commercial products, this metric reflects the discounted value of future revenues from inflammatory bowel disease therapies. The trend of the aggregate consensus price forecast is based on the probability of regulatory drug approval. However, the mathematical summation of forecasts does not guarantee a rise in share prices. Investors should consider the risk of capital freeze if macroeconomic conditions change.